文献速递焦虑、强迫与应激相关障碍

成人PTSD药物、心理及联合治疗的疗效与可接受性:网络荟萃分析

Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Meta-analysis.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

该网络荟萃分析纳入12项RCT共922名成人PTSD患者,比较心理治疗、药物治疗及联合治疗的疗效与可接受性。治疗结束时无任何治疗方式显示优势;长期随访中心理治疗优于药物治疗,联合治疗在网络荟萃分析中优于药物治疗,但配对荟萃分析未证实。三种治疗方式的可接受性无差异。

要点

  • 治疗结束时,心理治疗、药物治疗及联合治疗之间未显示显著疗效差异。
  • 长期随访中,心理治疗在改善PTSD症状上优于药物治疗。
  • 联合治疗在网络荟萃分析中优于药物治疗,但配对荟萃分析未证实;可接受性无差异。

核心结论

  • 心理治疗在长期随访中优于药物治疗,联合治疗在网络荟萃分析中优于药物治疗但配对分析未证实。
  • 治疗结束时未发现任何治疗方式具有优势,三种治疗方式的可接受性无差异。

研究设计与样本

  • 研究为系统检索Embase、MEDLINE、PsycINFO、Cochrane Controlled Trials Register和PSYNDEX(1980年1月1日至2018年2月28日)的网络荟萃分析。
  • 纳入12项随机临床试验共922名成人PTSD患者,提供23个直接比较。
  • 使用随机效应网络和配对荟萃分析聚合标准化均数差(SMD)和比值比,并评估偏倚风险和间接性。

主要发现

  • 治疗结束时,所有治疗方式比较的95%CI均包含0,无显著优势。
  • 末次随访时,心理治疗优于药物治疗:网络荟萃分析SMD=-0.83(95%CI -1.59至-0.07),配对荟萃分析SMD=-0.63(95%CI -1.18至-0.09,3项RCT)。
  • 联合治疗与心理治疗在长期随访中无差异;联合治疗优于药物治疗仅见于网络荟萃分析(SMD=-0.96,95%CI -1.87至-0.04),配对荟萃分析(2项RCT)SMD=-1.02(95%CI -2.77至0.72)。
  • 未发现三种治疗方式在可接受性(脱落率)上的差异证据。

关键数值与推荐

  • 主要结局为PTSD症状改善的疗效比较,次要结局为治疗终止前患者脱落率反映的可接受性。
  • 网络荟萃分析显示心理治疗优于药物治疗的SMD=-0.83(95%CI -1.59至-0.07)。
  • 配对荟萃分析显示心理治疗优于药物治疗的SMD=-0.63(95%CI -1.18至-0.09,3项RCT)。
  • 网络荟萃分析显示联合治疗优于药物治疗的SMD=-0.96(95%CI -1.87至-0.04)。
  • 配对荟萃分析显示联合治疗与药物治疗比较的SMD=-1.02(95%CI -2.77至0.72,2项RCT)。

临床怎么用

  • 长期治疗决策可优先考虑心理治疗,因其在随访中显示优于药物治疗。
  • 联合治疗对长期症状改善可能优于单纯药物治疗,但证据尚不稳健。
  • 治疗结束时三种方式疗效相当,选择需结合患者偏好与可及性。

局限性

  • 长期随访数据稀缺,妨碍确定性结论。
  • 纳入研究数量有限(12项RCT,922例),部分比较仅基于少量试验。
  • 需要大规模比较试验提供长期随访数据以验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Posttraumatic stress disorder (PTSD) is a prevalent mental disorder, with a high risk of chronicity, comorbidity, and functional impairment; PTSD is complicated to treat, and the debate on the best treatment approach is ongoing. OBJECTIVE: To examine comparative outcomes and acceptability of psychotherapeutic and pharmacological treatments and their combinations in adults with PTSD. DATA SOURCES: Embase, MEDLINE, PsycINFO, Cochrane Controlled Trials Register, and PSYNDEX were searched for studies published from January 1, 1980, to February 28, 2018. Reference lists of included studies and of previously published guidelines and systematic reviews were also searched. STUDY SELECTION: Of 11 417 records identified, 12 published randomized clinical trials (RCTs) comprising 922 participants, contributing 23 direct comparisons between psychotherapeutic and pharmacological treatments or their combinations were included. DATA EXTRACTION AND SYNTHESIS: Standardized mean differences (SMDs) and odds ratios were aggregated using random-effects network and pairwise meta-analyses. Risk of bias and indirectness was rated for each study, and network confidence was rated using the Confidence in Network Meta-Analysis framework. MAIN OUTCOMES AND MEASURES: The primary outcome was the comparative benefit between 2 treatment approaches to PTSD symptom improvement, and secondary outcome was the comparative acceptability of the treatment approaches, as indicated by patient dropout rates before treatment termination. RESULTS: No treatment approach was found to be superior at the end of treatment (for all, 95% CI included 0). At the last follow-up, psychotherapeutic treatments showed greater benefit than pharmacological treatments in both network (SMD, -0.83; 95% CI, -1.59 to -0.07) and pairwise (SMD, -0.63; 95% CI, -1.18 to -0.09, 3 RCTs) meta-analyses. No difference was found between combined treatments and psychotherapeutic treatments at long-term follow-up, and combined treatments were associated with better outcomes than pharmacological treatments in the network meta-analysis (SMD, -0.96; 95% CI, -1.87 to -0.04), but not in the pairwise meta-analysis, which included 2 RCTs (SMD, -1.02; 95% CI, -2.77 to 0.72). No evidence was found for differential acceptability of the 3 treatment approaches. CONCLUSIONS AND RELEVANCE: These results suggest superiority of psychotherapeutic treatments over pharmacological treatments; network, but not pairwise, meta-analyses suggest superiority of combined treatments over pharmacological treatments in improving PTSD symptom severity in the long term. The scarcity of reported long-term findings hampers definite conclusions and demonstrates the need for robust evidence from large-scaled comparative trials providing long-term follow-up data.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Merz J, Schwarzer G, Gerger H, et al. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Meta-analysis. JAMA Psychiatry. 2019. PMID: 31188399. doi:10.1001/jamapsychiatry.2019.0951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。